drugset / Trial / NCT07157007
Early-stage Trial to Determine a Safe and Effective Dose for Ratutrelvir in Patients With Mild to Moderate COVID-19
RandomizedParallel-groupOpen-labelTreatment
Summary
This is an Early-stage Clinical Trial to Determine a Safe and Effective Dose for Ratutrelvir in Patients With Mild to Moderate COVID-19. It will also learn about the safety of drug Ratutrelvir. Participants will take a study drug as well as a standard therapy. A descriptive statistics will be used to present the study results.
Timeline
- Start
- 2025-09-16
- Primary completion
- 2026-02
- Completion
- 2026-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Nirmatrelvir | Small molecule | — | — |
| Subject | Ratutrelvir | Unknown | — | — |
| Comparator | Ritonavir | Other / unclassified | — | — |